TY - JOUR
T1 - The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes
T2 - Sub-analysis from the A1chieve® study
AU - Hwang, Y. C.
AU - Kang, J. G.
AU - Ahn, K. J.
AU - Cha, B. S.
AU - Ihm, S. H.
AU - Lee, S.
AU - Kim, M.
AU - Lee, Byung Wan
N1 - Publisher Copyright:
© 2014 John Wiley & Sons Ltd.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Aims In this study, we compared the glucose-lowering effectiveness of insulin analogues and their combination according to baseline glycemic status in patients with type 2 diabetes (T2D) from the A1chieve® study conducted in Korea.Methods This sub-analysis from the A1chieve® study was a 24-week prospective, multicenter, non-interventional, open-labelled study. Of the 4058 patients, 3074 patients who had their HbA1c level measured at baseline were included in this sub-analysis. We classified patients into three groups according to baseline HbA1c levels: group I (HbA1c < 7.5%), group II (7.5% ≤ HbA1c < 9.0%) and group III (HbA1c ≥ 9.0%).Results Patients in group I showed no significant HbA1c reduction with any insulin regimens (detemir, aspart, detemir and aspart or biphasic aspart 30 (Novo Nordisk A/S, DK-2880 Bagsværd, Denmark) after 24 weeks of treatment. In group II, although HbA1c was decreased for all insulin regimens, there was no difference in mean HbA1c reduction among the four insulin regimens. In patients with a high baseline HbA1c level (group III), mean HbA1c reduction was the greatest in patients on a basal-bolus regimen (detemir and aspart, -3.50%) and lowest in patients on a bolus regimen (aspart, -1.81%; p < 0.001).Conclusion For optimal glycaemic control, a basal-bolus regimen may be adequate for Korean patients with poorly controlled T2D (HbA1c ≥ 9.0%).
AB - Aims In this study, we compared the glucose-lowering effectiveness of insulin analogues and their combination according to baseline glycemic status in patients with type 2 diabetes (T2D) from the A1chieve® study conducted in Korea.Methods This sub-analysis from the A1chieve® study was a 24-week prospective, multicenter, non-interventional, open-labelled study. Of the 4058 patients, 3074 patients who had their HbA1c level measured at baseline were included in this sub-analysis. We classified patients into three groups according to baseline HbA1c levels: group I (HbA1c < 7.5%), group II (7.5% ≤ HbA1c < 9.0%) and group III (HbA1c ≥ 9.0%).Results Patients in group I showed no significant HbA1c reduction with any insulin regimens (detemir, aspart, detemir and aspart or biphasic aspart 30 (Novo Nordisk A/S, DK-2880 Bagsværd, Denmark) after 24 weeks of treatment. In group II, although HbA1c was decreased for all insulin regimens, there was no difference in mean HbA1c reduction among the four insulin regimens. In patients with a high baseline HbA1c level (group III), mean HbA1c reduction was the greatest in patients on a basal-bolus regimen (detemir and aspart, -3.50%) and lowest in patients on a bolus regimen (aspart, -1.81%; p < 0.001).Conclusion For optimal glycaemic control, a basal-bolus regimen may be adequate for Korean patients with poorly controlled T2D (HbA1c ≥ 9.0%).
UR - http://www.scopus.com/inward/record.url?scp=84916221156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84916221156&partnerID=8YFLogxK
U2 - 10.1111/ijcp.12482
DO - 10.1111/ijcp.12482
M3 - Article
C2 - 25284679
AN - SCOPUS:84916221156
SN - 1368-5031
VL - 68
SP - 1338
EP - 1344
JO - Medical bookman and historian
JF - Medical bookman and historian
IS - 11
ER -
